Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories

Where are we now and barriers to meeting World Health Organization targets by 2030

Jess Howell, Alisa Pedrana, Benjamin C. Cowie, Joseph Doyle, Aneley Getehun, James Ward, Ed Gane, Chris Cunningham, Jack Wallace, Alice Lee, Jioji Malani, Alex Thompson, Margaret E. Hellard

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

Viral hepatitis affects more than 320 million people globally, leading to significant morbidity and mortality due to liver failure and hepatocellular carcinoma (HCC). More than 248 million people (3.2% globally) are chronically infected with hepatitis B virus (HBV), and an estimated 80 million people (1.1% globally) are chronically infected with hepatitis C virus (HCV). In 2015, more than 700 000 deaths were directly attributable to HBV, and nearly 500 000 deaths were attributable to HCV infection; 2–5% of HBV-infected people develop HCC per annum irrespective of the presence of cirrhosis, whereas 1–5% HCV-infected people with advanced fibrosis develop HCC per annum. The rapidly escalating global mortality related to HBV and HCV related viral hepatitis to be the 7th leading cause of death worldwide in 2013, from 10th leading cause in 1990. Australia, New Zealand, and Pacific Island Countries and Territories fall within the World Health Organization Western Pacific Region, which has a high prevalence of viral hepatitis and related morbidity, particularly HBV. Remarkably, in this region, HBV-related mortality is greater than for tuberculosis, HIV infection, and malaria combined. The region provides a unique contrast in viral hepatitis prevalence, health system resources, and approaches taken to achieve World Health Organization global elimination targets for HBV and HCV infection. This review highlights the latest evidence in viral hepatitis epidemiology and explores the health resources available to combat viral hepatitis, focusing on the major challenges and critical needs to achieve elimination in Australia, New Zealand, and Pacific Island Countries and Territories.

Original languageEnglish
Pages (from-to)40-48
Number of pages9
JournalJournal of Gastroenterology and Hepatology
Volume34
Issue number1
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • epidemiology
  • liver cancer
  • viral hepatitis

Cite this

@article{f7604191b29d47d588547a85dafe4372,
title = "Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030",
abstract = "Viral hepatitis affects more than 320 million people globally, leading to significant morbidity and mortality due to liver failure and hepatocellular carcinoma (HCC). More than 248 million people (3.2{\%} globally) are chronically infected with hepatitis B virus (HBV), and an estimated 80 million people (1.1{\%} globally) are chronically infected with hepatitis C virus (HCV). In 2015, more than 700 000 deaths were directly attributable to HBV, and nearly 500 000 deaths were attributable to HCV infection; 2–5{\%} of HBV-infected people develop HCC per annum irrespective of the presence of cirrhosis, whereas 1–5{\%} HCV-infected people with advanced fibrosis develop HCC per annum. The rapidly escalating global mortality related to HBV and HCV related viral hepatitis to be the 7th leading cause of death worldwide in 2013, from 10th leading cause in 1990. Australia, New Zealand, and Pacific Island Countries and Territories fall within the World Health Organization Western Pacific Region, which has a high prevalence of viral hepatitis and related morbidity, particularly HBV. Remarkably, in this region, HBV-related mortality is greater than for tuberculosis, HIV infection, and malaria combined. The region provides a unique contrast in viral hepatitis prevalence, health system resources, and approaches taken to achieve World Health Organization global elimination targets for HBV and HCV infection. This review highlights the latest evidence in viral hepatitis epidemiology and explores the health resources available to combat viral hepatitis, focusing on the major challenges and critical needs to achieve elimination in Australia, New Zealand, and Pacific Island Countries and Territories.",
keywords = "epidemiology, liver cancer, viral hepatitis",
author = "Jess Howell and Alisa Pedrana and Cowie, {Benjamin C.} and Joseph Doyle and Aneley Getehun and James Ward and Ed Gane and Chris Cunningham and Jack Wallace and Alice Lee and Jioji Malani and Alex Thompson and Hellard, {Margaret E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/jgh.14457",
language = "English",
volume = "34",
pages = "40--48",
journal = "Journal of Gastroenterology and Hepatology",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "1",

}

Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories : Where are we now and barriers to meeting World Health Organization targets by 2030. / Howell, Jess; Pedrana, Alisa; Cowie, Benjamin C.; Doyle, Joseph; Getehun, Aneley; Ward, James; Gane, Ed; Cunningham, Chris; Wallace, Jack; Lee, Alice; Malani, Jioji; Thompson, Alex; Hellard, Margaret E.

In: Journal of Gastroenterology and Hepatology, Vol. 34, No. 1, 01.01.2019, p. 40-48.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories

T2 - Where are we now and barriers to meeting World Health Organization targets by 2030

AU - Howell, Jess

AU - Pedrana, Alisa

AU - Cowie, Benjamin C.

AU - Doyle, Joseph

AU - Getehun, Aneley

AU - Ward, James

AU - Gane, Ed

AU - Cunningham, Chris

AU - Wallace, Jack

AU - Lee, Alice

AU - Malani, Jioji

AU - Thompson, Alex

AU - Hellard, Margaret E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Viral hepatitis affects more than 320 million people globally, leading to significant morbidity and mortality due to liver failure and hepatocellular carcinoma (HCC). More than 248 million people (3.2% globally) are chronically infected with hepatitis B virus (HBV), and an estimated 80 million people (1.1% globally) are chronically infected with hepatitis C virus (HCV). In 2015, more than 700 000 deaths were directly attributable to HBV, and nearly 500 000 deaths were attributable to HCV infection; 2–5% of HBV-infected people develop HCC per annum irrespective of the presence of cirrhosis, whereas 1–5% HCV-infected people with advanced fibrosis develop HCC per annum. The rapidly escalating global mortality related to HBV and HCV related viral hepatitis to be the 7th leading cause of death worldwide in 2013, from 10th leading cause in 1990. Australia, New Zealand, and Pacific Island Countries and Territories fall within the World Health Organization Western Pacific Region, which has a high prevalence of viral hepatitis and related morbidity, particularly HBV. Remarkably, in this region, HBV-related mortality is greater than for tuberculosis, HIV infection, and malaria combined. The region provides a unique contrast in viral hepatitis prevalence, health system resources, and approaches taken to achieve World Health Organization global elimination targets for HBV and HCV infection. This review highlights the latest evidence in viral hepatitis epidemiology and explores the health resources available to combat viral hepatitis, focusing on the major challenges and critical needs to achieve elimination in Australia, New Zealand, and Pacific Island Countries and Territories.

AB - Viral hepatitis affects more than 320 million people globally, leading to significant morbidity and mortality due to liver failure and hepatocellular carcinoma (HCC). More than 248 million people (3.2% globally) are chronically infected with hepatitis B virus (HBV), and an estimated 80 million people (1.1% globally) are chronically infected with hepatitis C virus (HCV). In 2015, more than 700 000 deaths were directly attributable to HBV, and nearly 500 000 deaths were attributable to HCV infection; 2–5% of HBV-infected people develop HCC per annum irrespective of the presence of cirrhosis, whereas 1–5% HCV-infected people with advanced fibrosis develop HCC per annum. The rapidly escalating global mortality related to HBV and HCV related viral hepatitis to be the 7th leading cause of death worldwide in 2013, from 10th leading cause in 1990. Australia, New Zealand, and Pacific Island Countries and Territories fall within the World Health Organization Western Pacific Region, which has a high prevalence of viral hepatitis and related morbidity, particularly HBV. Remarkably, in this region, HBV-related mortality is greater than for tuberculosis, HIV infection, and malaria combined. The region provides a unique contrast in viral hepatitis prevalence, health system resources, and approaches taken to achieve World Health Organization global elimination targets for HBV and HCV infection. This review highlights the latest evidence in viral hepatitis epidemiology and explores the health resources available to combat viral hepatitis, focusing on the major challenges and critical needs to achieve elimination in Australia, New Zealand, and Pacific Island Countries and Territories.

KW - epidemiology

KW - liver cancer

KW - viral hepatitis

UR - http://www.scopus.com/inward/record.url?scp=85053909779&partnerID=8YFLogxK

U2 - 10.1111/jgh.14457

DO - 10.1111/jgh.14457

M3 - Review Article

VL - 34

SP - 40

EP - 48

JO - Journal of Gastroenterology and Hepatology

JF - Journal of Gastroenterology and Hepatology

SN - 0815-9319

IS - 1

ER -